...
首页> 外文期刊>Regulatory peptides. >B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function.
【24h】

B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function.

机译:B型利钠肽水平可预测非ST段抬高型冠状动脉综合征和正常的左心室收缩功能中冠状动脉疾病的程度和严重程度。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: B-type natriuretic peptide (BNP) has been used recently as a biological marker in patients with coronary artery disease (CAD) with ST-elevation, as well as without ST-elevation. BNP is able to predict systolic dysfunction, adding new prognostic information to existing traditional markers. However is not known if there is a relation between the quantity of BNP levels and the severity of coronary artery disease. METHODS: This study compared B-type natriuretic peptide (BNP) levels in patients with stable angina (SA) and acute coronary syndromes (ACS) without ST-elevation in relation to angiographic lesions using TIMI and Gensini Scores. We studied 282 patients with CAD without ST elevation and preserved systolic function. BNP samples were measured in all recruited patients within 24 hours of hospitalization. RESULTS: BNP values were progressively increased in relation to the severity of diagnosis: SA (52.6+/-49.4 pg/mL ) UA (243.3+/-212 pg/mL) NSTE-ACS (421.7+/-334 pg/mL) (p<0.0001 and p<0.007 respectively). No statistically significant difference was observed between patients with SA and controls (21.2+/-6.8 pg/mL). The analysis of BNP levels in relation to the number of involved vessels demonstrated significantly increased levels in patients with multivessel disease compared to patients with 1 or 2 vessel disease (1-86.2+/-46.3 pg/mL; 2-127+/-297 pg/mL; 3-295+/-318 pg/mL; 4-297+/-347 pg/mL p<0.001 and p<0.003). Evaluation of BNP using Gensini Score showed a strong relation between BNP and coronary disease extension (r=0.38 p<0.0001).This trend was maintained in all CAD groups (SA=r 0.54; UA r=0.36 NSTE-ACS r=0.28). CONCLUSIONS: Circulating BNP levels appear elevated in ACS with diffuse coronary involvement, even in the absence of systolic dysfunction. BNP is also associated with multi-vessel disease and the extension of coronary disease.
机译:背景:B型利钠肽(BNP)最近已被用作具有ST抬高和无ST抬高的冠心病(CAD)患者的生物标志物。 BNP能够预测收缩功能障碍,为现有的传统标志物增加新的预后信息。但是,尚不清楚BNP水平的数量与冠状动脉疾病的严重程度之间是否存在关系。方法:本研究使用TIMI和Gensini评分比较了稳定型心绞痛(SA)和无ST抬高的急性冠脉综合征(ACS)患者与血管造影病变相关的B型利钠肽(BNP)水平。我们研究了282例无ST抬高且保留了收缩功能的CAD患者。在住院的24小时内对所有入组患者进行BNP样本测量。结果:BNP值相对于诊断的严重程度逐渐提高:SA(52.6 +/- 49.4 pg / mL)UA(243.3 +/- 212 pg / mL)NSTE-ACS(421.7 +/- 334 pg / mL) (分别为p <0.0001和p <0.007)。 SA患者和对照组(21.2 +/- 6.8 pg / mL)之间没有观察到统计学上的显着差异。 BNP水平与受累血管数量相关的分析表明,与1或2种血管疾病的患者相比,多支血管疾病患者的BNP水平显着增加(1-86.2 +/- 46.3 pg / mL; 2-127 +/- 297 pg / mL; 3-295 +/- 318 pg / mL; 4-297 +/- 347 pg / mL(p <0.001和p <0.003)。用Gensini评分评估BNP显示BNP与冠状动脉疾病扩展之间有很强的相关性(r = 0.38 p <0.0001),所有CAD组均保持这种趋势(SA = r 0.54; UA r = 0.36 NSTE-ACS r = 0.28) 。结论:即使在没有收缩功能障碍的情况下,ACS的循环血BNP水平也升高,伴有弥漫性冠状动脉受累。 BNP还与多支血管疾病和冠状动脉疾病的扩展有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号